<DOC>
	<DOCNO>NCT02761070</DOCNO>
	<brief_summary>The aim Phase III study evaluate superiority dose-dense temozolomide ( ddTMZ ) follow bevacizumab ddTMZ failure glioblastoma first recurrence progression , compare bevacizumab alone .</brief_summary>
	<brief_title>Bevacizumab Alone Versus Dose-dense Temozolomide Followed Bevacizumab Recurrent Glioblastoma , Phase III</brief_title>
	<detailed_description>Glioblastoma ( GBM ) , frequent malignant primary brain tumor , yet incurable despite recent progress standard care use TMZ main trunk initial therapy newly diagnose setting . One main reason account dismal prognosis would attribute lack active therapeutic regimen recurrence . Bevacizumab , humanize monoclonal antibody cardinal angiogenic factor vascular endothelial growth factor ( VEGF ) , recently show efficacy recurrent GBM , approve Japan , thereby standard care recurrent GBM . Since effective drug regimen develop bevacizumab failure , insertion another active drug prior bevacizumab induction would enhance survival time patient recurrent GBM . In Japan , currently chemotherapeutic agent approve available GBM . Among rechallenge alternate dose TMZ show certain efficacy acceptable toxicity patient TMZ-pretreated recurrent GBM , thus good candidate regimen use prior bevacizumab recurrence . The present proposal sequential administration dose dense TMZ ( 7/14d ) follow bevacizumab wish define new standard care recurrent disease hop identify subgroup patient progressive recurrent glioblastoma respond particularly well dose-dense temozolomide regimen . This study carry JCOG Brain Tumor Study Group multicenter randomize phase III trial approval Advanced Medical Care B system , Ministry Health , Labour Welfare , Japan .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Histologically proven diagnosis glioblastoma ( include giant cell glioblastoma gliosarcoma ) . 2 . For patient undergo surgery recurrent disease ; preregistration contrast MRI confirm ; ( ) progressive recurrent glioblastoma ; ( ii ) evidence acute subacute cerebral hemorrhage enrolment ; ( iii ) presence measurable lesion . 3 . For patient underwent surgery recurrent disease ; ( ) progressive recurrent glioblastoma must confirm contrast MRI reoperation ; ( ii ) glioblastoma anaplastic astrocytoma must histologically identify tissue resect reoperation ; ( iii ) presence measurable lesion mandatory preregistration contrast MRI ( 4 day reoperation ) ; ( iv ) MRI evidence aggravate cerebral hemorrhage . 4 . No evidence tumor cerebellum , brain stem , optic nerve , olfactory nerve , pituitary gland . 5 . No evidence meningeal dissemination gliomatosis cerebri . 6 . Prior treatment newlydiagnosed glioblastoma ( anaplastic astrocytoma ) postoperative TMZ administer concomitantly radiotherapy ( &gt; =54 Gy &lt; =69 year old ; &gt; =30 Gy &gt; =70 year old ) least two cycle ( 5/28d ) adjuvant treatment give . 7 . No history prior treatment stereotactic radiotherapy ( ex . Gammaknife/Cyberknife ) , proton beam irradiation , neutron capture therapy , chemotherapy except standard dose TMZ intraoperative placement carmustine wafer .glioblastoma . 8 . More 90 day completion radiotherapy . For underwent reoperation , 21 28 day postoperatively . 9 . Age 20 75 year enrolment . 10 . Karnofsky Performance Status &gt; = 60 within 14 day enrolment . 11 . No prior treatment chemotherapy , molecular target therapy , radiotherapy head neck area malignancy . 12 . Adequate organ function . 13 . Written informed consent . 1 . Synchronous metachronous ( within 5 year ) malignancy , except carcinoma situ mucosal tumor curatively treat local therapy 2 . Active infection require systemic therapy 3 . Body temperature &gt; = 38 degree Celsius registration 4 . Women pregnancy , possible pregnancy , within 28 day delivery , breastfeed 5 . Psychosis psychotic symptom 6 . Continuous systemic use immunosuppressant except steroid 7 . Uncontrolled diabetes mellitus routine administration insulin 8 . Unstable angina within 3 week , history myocardial infarction within 6 month , New York Heart Association ( NYHA ) class II great congestive heart failure 9 . Inadequately control hypertension ( control systolic pressure &gt; = 150 mmHg diastolic pressure &gt; = 100 mmHg ) 10 . History symptomatic cerebrovascular disorder ( include subarachnoid hemorrhage , cerebral infarction transient ischemic attack ) within 6 month history vascular disorder require intervention ( include venous/arterial thrombosis embolism aortic aneurysm ) within 6 moth 11 . History grade &gt; = 2 hemoptysis within 28 day 12 . History hemorrhagic tendency ( e.g. , coagulation disorder ) grade &gt; = 3 hemorrhage within 28 day 13 . History gastrointestinal perforation , fistula , abdominal abscess uncontrolled peptic ulcer within 6 month 14 . Interstitial pneumonia , pulmonary fibrosis , severe lung emphysema 15 . Severe nonhealing wound traumatic fracture enrolment 16 . Hypersensitivity Chinese Hamster Ovaryderived drug recombinant antibody 17 . Gadolinium allergy 18 . Positive HIV antibody 19 . Positive Hepatitis B ( HB ) antigen</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>recurrent</keyword>
	<keyword>dose-dense temozolomide</keyword>
	<keyword>bevacizumab</keyword>
</DOC>